B-Cure Laser

Neutral

The company אריקה בי קיור, controlled by Michael and Tzipora Shloser, is set to hold a stockholders meeting next week. Among the agenda items, the company proposes to grant Chairman Yaki Vadmani a salary package of 920,000 shekels, and the new CEO Ronen Goldstein a salary package of about 1.57 million shekels. The company, which was traded at a value of 1.5 billion shekels, is sold for only 17 million shekels.

growth-negative

The Israeli Securities Authority has begun enforcement proceedings against Erika Biocure following the companys report that it had received regulatory approval from the European Union for some of its products, when in fact it did not have such approval.

growth-negative

B-Cure Laser, an Israeli medical equipment company, has appointed Gideon Landsberger as its new CEO. This follows the dismissal of the previous CEO, Dr. Rom Eliaz, after only six months due to what the company described as his unsuitability for the role and a crisis of confidence. Landsberger previously served as CEO of Remedia, a baby food marketing company, and Apron Machines. B-Cure Laser, which was established in 2007, has seen its stock price fall by more than 90% since its IPO in 2021. The company also reported a 53% decrease in revenue in the first half of 2022, and a loss of 25.5 million shekels.

growth-negative

B-Cure Laser, an Israeli medical equipment company, has dismissed its CEO, Dr. Rom Eliaz, after only six months in the role. The company cited a lack of fit for the role and a crisis of trust as reasons for the dismissal. B-Cure Laser, which was established in 2007, has seen a dramatic decline in its share price, losing 96% of its value since its IPO last year. The company has also reported a 53% drop in revenue in the first half of 2022 and a loss of 25.5 million shekels. The companys financial situation remains uncertain, with only 35 million shekels in cash remaining.

growth-negative

Israeli company Arikha Bi-Cure, developer of the Bi-Cure Laser pain treatment device, has been experiencing a sharp decline in both revenue and share price in recent months. Two external directors have resigned, stating they no longer feel they can contribute to the company. The companys current valuation is 27 million shekels, after a 97% drop in share price since the beginning of the year. The company has also reduced its workforce from 150 employees in January 2022 to approximately 105. Arikha Bi-Cure is also facing a class-action lawsuit for 115 million shekels for misleading revenue forecasts.

growth-negative

Erika B-Cure Laser, a medical device company, has experienced a significant decline in its business and share price. The company went public at half the valuation it originally sought and raised about NIS 110 million from the public. However, the share price has collapsed, losing about 95% to date. Erika B-Cure Laser is now traded at a market cap of only NIS 35 million. The company is also facing a NIS 115 million lawsuit over a misleading detail in its prospectus. The lawsuit claims that the companys forecast revenue for 2021 was far from reality. Erika B-Cure Laser attributes its sales decline to changes in the digital sector, privacy policies, and the end of COVID-19 restrictions. The company plans to implement efficiency measures, including reducing its workforce by 30%.

growth-negative

אריקה בי־קיור לייזר, a company that markets a laser device for pain treatment, has reported a 47% drop in sales for the first half of 2022, resulting in an operational loss of 23.6 million shekels. The company attributes the decline to customers returning to clinics for treatment post-COVID-19 and difficulties in collecting payments from customers in England. The company has also undergone management changes and laid off 30% of its workforce as part of a recovery plan.

growth-negative

בי-קיור לייזר, a company that sells products for pain relief, has experienced a significant decline in sales and expects a 45% decrease in revenue compared to 2021. The company also anticipates significant operational losses due to rising advertising prices. As a result, the company has initiated a cost-cutting plan, including potential layoffs and other measures to improve financial results. The company attributes the sales decline to advertising price increases and changes in privacy policies in its digital advertising channels. Despite having a cash balance of approximately 36 million shekels, the company expects a substantial decrease in sales in the coming months. Several senior executives have resigned, and the companys owner has appointed a new CEO. The company plans to implement additional cost-cutting measures and reduce marketing expenses.

growth-negative

The medical equipment company, Arikha Biocure, has recently experienced a sharp decline in its stock due to missed forecasts and a shift to loss. This has been accompanied by a wave of senior resignations, including the CEO, CFO, and several other key roles. The companys owner, Miki Shloser, has stated that they are currently hiring a new international marketing director and believes the company is moving in the right direction. Arikha Biocure, which develops and markets a medical device for pain treatment, has also recently acquired the distribution rights for a new product from another company owned by Shloser.

growth-negative

Arikha Bi-Cure Laser, a medical device company, has seen a significant decline in its stock price, with a 60% contraction since its initial public offering. The companys CEO, Motti Nevon, has resigned, following the resignation of the CFO and International Operations Manager, Nir Barb, last month. The company, which developed and markets a medical device for pain treatment, was initially valued at 800 million shekels during its IPO on the Tel Aviv Stock Exchange last year. However, the companys value has now dropped to around 200 million shekels. The companys founder, Miki Shloser, currently holds about 74% of its shares.

growth-positive

Arika Carmel has received approval from the Canadian Ministry of Health to market and sell its laser-based medical device, Bi-Cure Laser, in Canada. The company plans to start marketing and selling the product in November. This approval signifies the growing global demand for pain treatment and orthopedic solutions. Arika Carmel already has approvals in the UK, where sales account for about 25% of the companys total sales, and has submitted an application to the FDA in the US. The company is also in the process of seeking regulatory approval in China. Arika Carmel went public on the Tel Aviv Stock Exchange in August, raising approximately 108 million NIS.

growth-negative

Erika Carmel, a developer and marketer of pain relieving medical device B Cure Laser, has revised its IPO prospectus, cutting its valuation from NIS 800 million to NIS 430 million. The company plans to raise nearly NIS 90 million, while existing shareholders will sell holdings worth NIS 20 million. The decrease in valuation is attributed to the market becoming more selective. The decline in the number of players and recent acquisitions in the market have made it tougher for offerings to proceed. Large institutions have the power to bring down the price. The article was published on July 22, 2021.

growth-positive

B-Cure Laser, a company that produces medical devices for pain and orthopedic treatment, is planning to go public on the Tel Aviv Stock Exchange. The company, led by founder and chairman Miki Shloser, is looking to raise between 200-250 million shekels at a valuation of around 1 billion shekels. The aim of the IPO is to expand the companys operations abroad.

growth-positive

The article discusses the B-Cure Laser, a soft laser home treatment device developed by Israeli company Erika Carmel Ltd. The device effectively treats pain and orthopedic problems such as back pain, neck and knee pain, and tennis elbow. It harnesses the power of large and expensive laser machines found in pain clinics, producing similar results using a small hand-held device. The B-Cure Laser encourages the bodys natural healing powers, invigorates blood flow, releases endorphins, and reduces inflammation. The device is lightweight, easy to operate, and safe. It is already present in over 10,000 Israeli homes and is also used in hospitals. The article highlights positive testimonials from patients and recommends the device for athletes and sports injuries. The B-Cure Laser is approved by the Health Ministry.

growth-positive

The article discusses B-Cure Laser, an Israeli invention that provides clinical soft laser therapy in a portable and user-friendly medical device. It is the first portable soft laser device with the healing power of a full-sized machine used in hospitals. B-Cure Laser uses low-level laser technology to treat pain, wounds, burns, sports injuries, inflammation, acne, and skin rejuvenation. The device is rechargeable and can be used at home, providing effective and unlimited treatments. The article highlights the growth-positive impact of B-Cure Laser, as it expands its customer base and offers a convenient solution for pain management and treatment.